Artikkel

School of Pharmacy to collaborate with AstraZeneca in type 2-diabetes research

School of Pharmacy to collaborate with AstraZeneca in type 2-diabetes research

The University of Oslo has entered a five-year research agreement with AstraZeneca in the area of type 2 diabetes. As part of the agreement, four researchers from the University will work at AstraZeneca’s laboratories in Sweden.

Henrik Schultz
"We hope that this partnership will give new knowledge and contribute to the development of better treatments for type 2 diabetes", says Henrik Schultz. Photo: Gunhild M. Haugnes/UiO. Download picture.

“I am very pleased with this agreement. This collaboration will give our researchers the opportunity to work with AstraZeneca’s frontline scientists in the diabetes area and give them access to AstraZeneca’s modern research laboratories in Gothenburg, Sweden, where they will be able to use state-of-the-art equipment that we do not possess ourselves. The partner-ship will be jointly funded”, says Henrik Schultz, Head of the School of Pharmacy at the UiO.

“We hope that through this partnership we will gain new knowledge and contribute to the development of better treatments for type 2 diabetes in the future”, he adds.

The head of the School of Pharmacy points out that the agreement is a good example of how academic and industrial research can join forces to encourage innovation.

“With this project, we will also follow up the Norwegian government’s ambition to work more closely with international and industrial partners in the area of medical research. The School of Pharmacy has been working towards this goal for some time”, Schultz explains.

“We discussed several potential areas for joint research projects, and found that we had a sound common ground in type 2-diabetes”, he adds.

Academic and industry partnerships

According to Marcus Schindler, Vice President, Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca, this collaboration exemplifies the company’s efforts to foster academic and industry partnerships in order to jointly drive scientific progress in the Nordic region and capitalise on the next generation of scientists.

AstraZeneca
AstraZenecas research facility outside, Gøteborg. Photo: AstraZeneca

“Type 2 diabetes is an area of great unmet medical need. We are pleased to be working with the University of Oslo in this important area of medical science“, Schindler says.

“The School of Pharmacy and AstraZeneca are already collaborating in a more traditional research project in the area of obesity, together with the Vestfold Hospital Trust and their unit for research into this disease. We have very good experience and results from this project, which again gives us great expectations for the new project,” says Schultz.

Contact:

Head of Department Henrik Schultz, UiO School of Pharmacy